
Insights
-
09 April, 2025 Regulatory Affairs Articles
Navigating Labelling Exemptions: Strategies for Market Access (Part II)
-
07 April, 2025 Pharmacovigilance Articles
Pharmacovigilance System Set-Up
-
03 April, 2025 Regulatory Affairs Articles
Comparison of the CEP and ASMF Procedures
-
27 March, 2025 Pharmacovigilance Articles
Pharmacovigilance Regulations in France: Specifics You Need to Know
-
26 March, 2025 Regulatory Affairs Webinars
Labelling Exemptions and Foreign Language Packs in EU/EEA
-
24 March, 2025 Regulatory Affairs Articles
e-PI Pilot projects overview
-
19 March, 2025 Pharmacovigilance Regulatory Affairs Articles
Pharmaceutical marketing. How to ensure compliance?
-
18 March, 2025 Pharmacovigilance Articles
Implementation of Educational Materials on the National Level
-
12 March, 2025 Pharmacovigilance
Pharmacovigilance in Switzerland: Navigating Unique Regulatory Challenges
-
05 March, 2025 Regulatory Affairs Articles
Nitrosamines – what you need to know and consider for new Marketing Authorisation Applications
-
04 March, 2025 Company news
Insuvia Ranks in FT1000 Fastest Growing Companies in Europe
-
21 February, 2025 Pharmacovigilance Articles
Breaking Stereotypes of Local Literature Review
-
18 February, 2025 Pharmacovigilance Articles
Clinical Safety Management Plan and its Importance
-
06 February, 2025 Pharmacovigilance Articles
How to manage pharmacovigilance effectively in compassionate use programs
-
06 February, 2025 Pharmacovigilance Articles
ISO IDMP standards implementation. What should MAHs prepare for?